Status | Study |
Not yet recruiting |
Study Name: Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization Condition: Corneal Neovascularization Date: 2016-05-24 Interventions: Drug: Aflibercept Other Name: Eylea |
Not yet recruiting |
Study Name: Strategies for Management of Corneal Neovascularisation Condition: Corneal Neovascularisation Date: 2015-10-27 Interventions: Device: Fine Needle Diathermy |
Withdrawn |
Study Name: Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions Condition: Corneal Neovascularization Corneal Graft Failure Date: 2014-01-17 Interventions: Drug: Gamunex-C Patients will receive 50 mg (0.5 mL) subconjunctival Gamunex-C injection in addition to |
Recruiting |
Study Name: A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival Condition: Corneal Neovascularization Corneal Graft Failure Date: 2013-11-22 Interventions: Drug: Avastin® (bevacizumab) |
Terminated |
Study Name: Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea Condition: Corneal Neovascularization Date: 2013-05-15 Interventions: Drug: Subconjunctival aflibercept |
Recruiting |
Study Name: Investigation of Different Scanning Protocols for 3 Dimensional High-resolution Imaging of the Human Cornea With Optical Coherence Tomography (OCT) - A Pilot Study Condition: Corneal Neovascularisation Keratoconus Date: 2013-04-26 Interventions: Device: Optical Coherence Tomography Imaging of the cornea using ultrahigh resolution Spectral Domain OC |
Completed |
Study Name: Treatment of Corneal Neovascularization With Topical Pazopanib Condition: Corneal Neovascularization Date: 2010-11-22 Interventions: Drug: Pazopanib (5mg/ml) Topical pazopanib, 4 times per day for 3 weeks |
Completed |
Study Name: Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival Condition: Corneal Neovascularization Corneal Graft Failure Date: 2010-02-18 Interventions: Drug: Avastin® (bevacizumab) |
Completed |
Study Name: Bevacizumab for the Treatment of Corneal Neovascularization Condition: Corneal Neovascularization Date: 2009-10-08 Interventions: Drug: Bevacizumab Topical 10 mg/cc or subconjunctival 2.5 mg/0.1cc |
Terminated |
Study Name: Topical IL-1-Ra for Treatment of Corneal Neovascularization Condition: Corneal Neovascularization Date: 2009-06-04 Interventions: Drug: Placebo Custom eye drop |